Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.

Oral Oncol

Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan. Electronic address:

Published: March 2022

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.oraloncology.2022.105729	DOI Listing

Publication Analysis

prognostic neutrophil-to-lymphocyte

neutrophil-to-lymphocyte ratio

ratio platelet-to-lymphocyte

platelet-to-lymphocyte ratio

ratio immune

immune checkpoint

checkpoint inhibitor

inhibitor treatment

treatment recurrent

recurrent metastatic

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!